Core Viewpoint - Heptagon Pharmaceuticals-B (02142) has seen a stock price increase of over 5%, currently trading at HKD 13.36, with a trading volume of HKD 85.495 million. The company announced a placement agreement to issue 45.022 million shares at HKD 11.50 each, representing a discount of approximately 9.45% from the closing price of HKD 12.70 on August 28, 2025. The net proceeds of approximately HKD 511.7 million will be allocated to R&D for innovative drug assets, clinical trials for existing pipeline drugs, and general corporate purposes [1]. Financial Performance - Heptagon Pharmaceuticals recently reported interim results with revenue of approximately USD 101 million, reflecting a year-on-year increase of about 327%. The net profit for the period was USD 72.999 million, showing a significant year-on-year growth of 5,125%. The increase in revenue was primarily driven by licensing fees, which rose from USD 20.8 million to USD 93.7 million due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products. Additionally, research services and technology licensing fees increased by 164.9%, from USD 2.9 million to USD 7.6 million [1].

Core Viewpoint - Heptares Therapeutics-B (02142) has seen a stock price increase of over 5%, currently trading at HKD 13.36, with a transaction volume of HKD 85.495 million [1] Group 1: Fundraising and Share Placement - Heptares Therapeutics-B announced a share placement agreement with a placement agent, agreeing to issue 45.022 million shares at a price of HKD 11.50 per share, which represents a discount of approximately 9.45% compared to the closing price of HKD 12.70 on August 28, 2025 [1] - If all shares are fully subscribed, the net proceeds are expected to be approximately HKD 511.7 million, with about 50% allocated for the development of innovative drug assets, 40% for advancing existing pipeline drug assets in clinical trials, and 10% for working capital and other general corporate purposes [1] Group 2: Financial Performance - Heptares Therapeutics-B reported a mid-term revenue of approximately USD 101 million, representing a year-on-year increase of about 327% [1] - The company achieved a profit of USD 72.999 million during the same period, reflecting a year-on-year growth of 5,125% [1] - Revenue from licensing fees increased from USD 20.8 million to USD 93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products [1] - Revenue from research services and technology licensing fees rose by 164.9%, from USD 2.9 million to USD 7.6 million [1]